文献速递支持与姑息治疗

客观缓解率和无进展生存期作为总生存期治疗效应的替代指标:跨越不同肿瘤组和当代疗法的荟萃分析

Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies.
PubMed 文献 · Eur J Cancer · 2023-12-18

该荟萃分析纳入2010年1月1日至2022年6月30日发表的675项3期随机对照试验、共350112例患者,评估客观缓解率(ORR)和无进展生存期(PFS)作为总生存期(OS)治疗效应替代指标的有效性。结果显示ORR(R²=0.10)和PFS(R²=0.38)均为OS的劣质替代指标,且替代强度因治疗和肿瘤类型而异。

要点

  • ORR(R²=0.10)和PFS(R²=0.38)均为OS治疗效应的劣质试验级替代指标。
  • PFS替代强度因治疗类型而异:化疗最高(R²=0.56),靶向治疗最低(R²=0.40)。
  • PFS在黑色素瘤(R²=0.72)和胰腺癌(R²=0.70)中替代水平最高。

核心结论

  • ORR和PFS是OS的劣质试验级替代指标。
  • ORR和PFS的替代表现因治疗和恶性肿瘤亚型而异。

研究设计与样本

  • 评估2010年1月1日至2022年6月30日发表的实体恶性肿瘤3期随机对照试验,这些试验报告了OS/PFS和ORR。
  • 通过加权线性回归评估替代终点与OS治疗效应的关系,决定系数(R²)量化回归模型的拟合度。
  • 共分析675项3期随机对照试验,包含350112例患者。

主要发现

  • ORR(R²=0.10)和PFS(R²=0.38)是OS治疗效应的劣质替代标志物。
  • 替代强度在治疗组和肿瘤组内部存在差异。
  • PFS的R²在化疗中最高(0.56),在靶向治疗中最低(0.40)。
  • PFS在黑色素瘤(R²=0.72)和胰腺癌(R²=0.70)中替代水平最高。
  • ORR与PFS之间相关性也较差(R²=0.33)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Overall survival (OS) results from randomized control trials (RCT) provide the strongest evidence for efficacy of anti-cancer treatments but can take a considerable amount of time to mature. Progression free survival (PFS) and objective response rate (ORR) are used as an early surrogate of OS treatment effect however their validity remains unclear. Our study aims to comprehensively evaluate ORR and PFS as surrogates for OS treatment effect across tumor groups and treatment types. MATERIAL AND METHODS: Phase 3 RCTs in solid malignancies that reported OS/PFS and ORR published between 1st of January 2010 and 30th of June 2022 were evaluated. The relationship of surrogate endpoints and OS treatment effect was assessed via weighted linear regression. The coefficient of determination (R2) quantified the fit of the regression model. RESULTS: 675 phase 3 RCT comprising of 350 112 patients were analysed. ORR (R2 of 0.10) and PFS (R2 of 0.38) were poor surrogate markers of OS treatment effect. The strength of surrogacy differed within treatment and tumour groups. PFS had the highest R2 for chemotherapy (0.56) and lowest for targeted therapy (0.40). PFS had the highest level of surrogacy for melanoma (R2 = 0.72) and pancreatic cancer (R2 = 0.70) compared to other tumour groups. Importantly ORR and PFS were also poorly correlated to each other (R2 = 0.33). CONCLUSIONS: ORR and PFS were poor trial-level surrogate markers of OS. The surrogacy performance of ORR and PFS differed by treatment and malignancy sub-type.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Shahnam A, Hitchen N, Nindra U, et al. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies. Eur J Cancer. 2023. PMID: 38134560. doi:10.1016/j.ejca.2023.113503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。